Insider Trading Activity Cardiovascular Systems Inc (NASDAQ:CSII) – General Counsel Sold 219 shares of Stock

13

Insider Trading Activity For Cardiovascular Systems Inc (NASDAQ:CSII)

Alexander Rosenstein , General Counsel of Cardiovascular Systems Inc (NASDAQ:CSII) reportedly Sold 219 shares of the company’s stock at an average price of 32.3 for a total transaction amount of $7,073.70 SEC Form

Insider Trading History For Cardiovascular Systems Inc (NASDAQ:CSII)

  • On 8/23/2012 Paul A Koehn, VP, sold 2,496 with an average share price of $9.07 per share and the total transaction amounting to $22,638.72. View SEC Filing
  • On 8/23/2012 Laurence L Betterley, CFO, sold 4,770 with an average share price of $9.07 per share and the total transaction amounting to $43,263.90. View SEC Filing
  • On 8/23/2012 James E Flaherty, Insider, sold 4,018 with an average share price of $9.07 per share and the total transaction amounting to $36,443.26. View SEC Filing
  • On 8/23/2012 David Martin, CEO, sold 10,510 with an average share price of $9.07 per share and the total transaction amounting to $95,325.70. View SEC Filing
  • On 11/13/2012 Glen D Nelson, Director, bought 33,000 with an average share price of $11.96 per share and the total transaction amounting to $394,680.00. View SEC Filing
  • On 5/13/2013 Glen D Nelson, Director, bought 18,393 with an average share price of $18.11 per share and the total transaction amounting to $333,097.23. View SEC Filing
  • On 5/16/2013 Glen D Nelson, Director, bought 4,753 with an average share price of $18.93 per share and the total transaction amounting to $89,974.29. View SEC Filing
  • Analyst Ratings For Cardiovascular Systems Inc (NASDAQ:CSII)
    These are 1 Hold Rating, 4 Buy Ratings, 1 Strong Buy Rating .
    The current consensus rating for Cardiovascular Systems Inc (NASDAQ:CSII) is Buy (Score: 3.00) with a consensus target price of $33.40 , a potential (6.13% upside)

    Analyst Ratings History For Cardiovascular Systems Inc (NASDAQ:CSII)

    • On 10/8/2015 Benchmark Co. Lower Price Target of rating Buy with a price target of $49.00 to $20.00
    • On 10/8/2015 Dougherty & Co Lower Price Target of rating Buy with a price target of $50.00 to $32.00
    • On 10/8/2015 William Blair Reiterated Rating Outperform
    • On 12/23/2015 Northcoast Research Initiated Coverage of rating Buy with a price target of $18.00
    • On 8/4/2016 Bank of America Corp Upgraded rating Underperform to Neutral
    • On 10/7/2016 JMP Securities Initiated Coverage of rating Outperform with a price target of $35.00
    • On 10/27/2016 Feltl & Co. Upgraded rating Buy to Strong-Buy with a price target of $30.00

    About Cardiovascular Systems Inc (NASDAQ:CSII)
    Cardiovascular Systems, Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications. Its peripheral artery disease (PAD) systems are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee. Its products include Diamondback 360 Peripheral Orbital Atherectomy System (OAS) (Diamondback 360 Peripheral), the Stealth 360 OAS (Stealth 360), Diamondback 360 Peripheral, Diamondback 360 60cm Peripheral, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral and Diamondback 360 2.00 Peripheral. The Company’s coronary arterial disease (CAD) product, Diamondback 360 Coronary OAS (Coronary OAS), is marketed as a treatment for severely calcified coronary arteries.

    Recent Trading Activity for Cardiovascular Systems Inc (NASDAQ:CSII)
    Shares of Cardiovascular Systems Inc closed the previous trading session at 31.49 up +0.02 0.06% with 194,740 shares trading hands.

    An ad to help with our costs